Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
Article content
SEATTLE — Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowing reproducible and iterative development and application of organoids.
Article content
Organoids are three-dimensional cellular models that recapitulate key aspects of organ function. They are used in safety and toxicology screening, drug discovery, disease modeling, and personalized medicine and could replace many instances where animal testing is required. However, organoid use has been hindered by lengthy and highly variable processes to make iPSC aggregates. The PluriForm Organoid Kit solves this challenge by providing a ready-to-use system that includes cryopreserved, Ready-to-Differentiate® (RTD®), suspension-adapted iPSCs and optimized media with a simple protocol. Each kit contains a vial of 25 million cells and all necessary reagents. Within minutes, the end-user can combine the components and generate thousands of uniform aggregates in just one day. These pluripotent aggregates display consistent morphology and size distribution, critical parameters for reproducible differentiation to a wide range of organoids, including neuronal, liver, intestinal, pancreatic, kidney, and cardiac models.
Article content
'Our goal is to accelerate the pace of discovery in the pharmaceutical and biotech industries,' said Dr. Benjamin Fryer, Co-founder and CEO of Pluristyx. 'With PluriForm, we have addressed consistent feedback that the initial step of creating reproducible cell aggregates is a major source of delay and inconsistency in organoid workflows.'
Article content
The FDA's Roadmap to Reduced Animal Testing in Preclinical Safety Studies, released in April 2025, explicitly advocates use of organoids to replace animal models. The PluriForm™ Organoid Kit is essential to enabling and accelerating the transition away from use of animals and other less-than-optimal cell assays and is now available for purchase through Pluristyx direct sales channels.
Article content
About Pluristyx
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
TD Cowen Sticks to Their Buy Rating for PNC Financial (PNC)
TD Cowen analyst maintained a Buy rating on PNC Financial (PNC – Research Report) today and set a price target of $233.00. The company's shares closed yesterday at $177.74. Confident Investing Starts Here: The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PNC Financial with a $195.38 average price target. PNC market cap is currently $70.97B and has a P/E ratio of 12.67. Based on the recent corporate insider activity of 101 insiders, corporate insider sentiment is neutral on the stock. Last month, Mark Wiedman, the President of PNC bought 20.00 shares for a total of $3,568.00.
CTV News
34 minutes ago
- CTV News
Retailer Roots reports $7.9M Q1 loss, sales up 6.7 per cent from year ago
TORONTO — Roots Corp. reported a first-quarter loss of $7.9 million compared with a loss of $8.9 million a year earlier as its sales rose 6.7 per cent. The retailer says the loss amounted to 20 cents per share for the quarter ended May 3 compared with a loss of 22 cents per share in the same quarter last year. Sales totalled $40.0 million, up from $37.5 million. The increase came as direct-to-consumer sales, which include corporate retail store and e-commerce sales, totalled $34.6 million, up from $31.4 million a year earlier. Roots says direct-to-consumer comparable sales growth was 14.1 per cent. Partners and other sales, which include wholesale Roots branded products, licensing to select partners and certain custom products, amounted to $5.4 million, down from $6.1 million in the same quarter last year. This report by The Canadian Press was first published June 13, 2025.
National Post
36 minutes ago
- National Post
Cizzle Brands Corporation Releases its Fiscal Q3 2025 Results, Reflecting Net Sales Growth of Over 25% for the Quarter
Article content During the first three quarters of its 2025 fiscal year, Cizzle Brands generated more than CAD $9.2 million in revenue, mainly from sales of CWENCH Hydration™, while maintaining a 52% gross margin in its fiscal Q3. Article content TORONTO — Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (the 'Company' or 'Cizzle Brands'), has released its financial results for the third quarter of its 2025 fiscal year (three months ended April 30, 2025, referred to herein as ' FQ3 2025 '). Article content Article content Key highlights from Cizzle Brands' FQ3 2025 results include the following (all figures are in Canadian Dollars unless otherwise specified): Article content Net sales of $3,577,113 during FQ3 2025, reflecting 25.24% sequential quarter-over-quarter (' QoQ ') growth from the previous fiscal quarter, bringing total revenues to $9.2 million for the nine months ended April 30, 2025; Gross profit increased by 14% to $1.87 million in FQ3 2025 from $1.64 million in the Company's previous fiscal quarter; Gross margin for the nine months ended April 30, 2025 was 57%; During FQ3 2025, reported U.S. sales grew 73% compared to the previous fiscal quarter, reflecting the Company's increased focus on key markets in the United States; and QoQ increase in Trade Receivables of 28.03% to $3,058,766, reflecting sustained growth of the Company's sales pipeline and a greater amount of Inventory on hand at $3,572,717, or an increase 14.43% over its previous fiscal quarter with no obsolete inventory and no provisions to inventory having been recorded. Article content Please refer to Cizzle Brands' profile on SEDAR+ ( to view the Company's full FQ3 2025 financial statements, as well as its corresponding Management Discussion and Analysis (' MD&A '). Article content Notable developments for Cizzle Brands during its FQ3 2025 period are summarized below. Article content Total count of retailers and other locations carrying CWENCH Hydration™ products across North America and Europe grew to over 3,000 points of distribution; CWENCH Hydration™ became the Official Hydration Partner of USA Hockey, the national governing body of ice hockey in the United States with more than one million players, coaches, officials, and volunteers across the country; CWENCH Hydration™ became the title sponsor of the CWENCH All Canadian Basketball Games and CWENCH All Canadian Volleyball Games; The Company launched CWENCH Hydration™ in a number of key retailers: London Drugs, MacEwen-owned gas stations, Canco Petroleum, Healthy Planet, Farm Boy, and Fortinos. In addition, CWENCH was launched at Metro locations in Ontario and subsequently expanded to Quebec; CWENCH Hydration™ was placed in United Supermarkets (Texas), further adding to the brand's presence in the United States; and The Company graduated to the OTCQB® Venture Market, and the Company's common shares became eligible for electronic deposit at the Depository Trust Company (' DTC ') which simplifies the process of trading CZZLF shares for U.S. investors. Article content Corporate Updates Article content In addition to release of the FQ3 2025 Financial Statements, Cizzle announced today that it has filed with the securities regulatory authorities in Ontario, British Columbia, and Alberta a notice of intention to be qualified to file a short form prospectus under National Instrument 44-101 – Short Form Prospectus Distributions, and an Annual Information Form. The filings qualify Cizzle Brands as a short-form prospectus filer but do not evidence its intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. Article content The Company also continues to evaluate a range of strategic alternatives to drive growth and maximize shareholder value as part of its ongoing review. Management is considering options to ensure each business unit is well-positioned, properly resourced, and focused on long-term value creation. Potential actions may include refining the Company's business strategy, focusing on specific products, markets, or partners; asset or business unit transactions; strategic investments; partnerships or joint ventures; or changes to capital structure and allocation. There is no assurance that this process will result in any specific action or transaction, or regarding the timing or outcome if one does occur. Article content Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, 'With the completion of Cizzle Brands' FQ3 2025, it is amazing to consider how much our team accomplished in under one calendar year. While many early-stage sports nutrition companies struggle to drive awareness, our disciplined approach has enabled us to be taken on by several leading Canadian retailers, in addition to Van Houtte Coffee Services Inc., a subsidiary of Keurig Dr Pepper Canada, and leading U.S. organizations such as USA Hockey and LifeTime. These accomplishments have generated quantifiable results, anchored by over CAD $9.2 million in net sales fiscal year-to-date with a gross margin of 57%, and over 3,000 locations carrying CWENCH Hydration products across North America and Europe. This is only the beginning, and on behalf of the Cizzle Brands team we are grateful to all of our investors, partners, and stakeholders who have contributed to the Company's phenomenal performance in its early stages.' Article content About Cizzle Brands Corporation Article content Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 3,000 locations in Canada, the United States, and Europe; and (ii) SPOKEN™ Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle. Article content This news release contains 'forward-looking information' which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Article content Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change. Article content Article content Article content Article content Contacts Article content For further information, please contact: Article content Article content Setti Coscarella Article content Article content Article content
